CROs in China
Low Cost Offshore Outsourcing
A Special Webcast Presented by Gerson Lehrman Group Life Sciences
Wednesday, April 20
11:30 AM EDT / 8:30 AM PDT
Bristol-Myers Squibb’s (NYSE:BMY) deal with China’s WuXi PharmaTech (NYSE:WX) is the most recent of an increasing number of collaborations between multinational pharmaceutical companies and contract research organizations (CROs) in China.
Join Dr. Makarand Jawadekar, former Vice President of the Asia Candidate Research Group at Pfizer Inc., and Dr. Jim Zhang, President and Founder of JZMed, Inc, a leading pharmaceutical outsourcing service provider specializing in pharmaceutical outsourcing in China, for a discussion on the growing CRO market in China.
* Why pharmaceutical companies enlist China’s CRO services
* Pharmaceutical companies’ decision making process for CROs
* China CRO companies and how they compare
Makarand Jawadekar, PhD
Former Vice President, Asia Candidate Research Group
Jim Zhang, PhD
President and Founder
Post a Comment